Publications by authors named "J Harmenberg"

Claim this Profile
M
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Johan Harmenberg

Lancet Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Sara Bringhen, Peter M Voorhees, Torben Plesner, Ulf-Henrik Mellqvist, Brandi Reeves, Johan Harmenberg

Br J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Paul G Richardson, Albert Oriol, Alessandra Larocca, Joan Bladé, Michele Cavo, Johan Harmenberg

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Paul G Richardson, Sara Bringhen, Peter Voorhees, Torben Plesner, Ulf-Henrik Mellqvist, Johan Harmenberg

Lancet Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response.
Robert Aiken, Magnus Axelson, Johan Harmenberg, Maria Klockare, Olle Larsson

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis